Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E Champlin

Showing results (101-110 of 766) with videos related to

Pageof 77
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 18, 2004
Graft--versus--breast cancer effect by allogeneic hematopoietic stem-cell transplantation: a possible new frontierNaoto T Ueno, Elizabeth J Shpall, Richard E Champlin, et al.
Bone Marrow Transplantation|November 7, 2002
Long-term follow-up of normal peripheral blood progenitor cell donors treated with filgrastim: no evidence of increased risk of leukemia developmentP Anderlini, F A Chan, R E Champlin, et al.
Cancer|November 25, 2003
Sequential interleukin 3 and granulocyte-macrophage-colony stimulating factor therapy in patients with bone marrow failure with long-term follow-up of responsesHillary H Wu, Moshe Talpaz, Richard E Champlin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 10, 2010
Primary systemic amyloid light chain amyloidosis decompensating after filgrastim-induced mobilization and stem-cell collectionQaiser Bashir, Lauren A Langford, Simrit Parmar, et al.
Nature Clinical Practice. Oncology|February 1, 2008
Gonadal failure after treatment of hematologic malignancies: from recognition to management for health-care providersKazutaka Nakayama, Andrea Milbourne, Leslie R Schover, et al.
Gynecologic Oncology|January 31, 2004
Matched unrelated donor bone marrow transplantation for the treatment of platinum refractory ovarian carcinoma: a case reportMichele L Donato, Charles Levenback, David M Gershenson, et al.
The Oncologist|January 28, 2012
Phase II study of gonadotropin-releasing hormone analog for ovarian function preservation in hematopoietic stem cell transplantation patientsYee Chung Cheng, Mariko Takagi, Andrea Milbourne, et al.
Biochemical Pharmacology|October 12, 2010
The synergistic cytotoxicity of clofarabine, fludarabine and busulfan in AML cells involves ATM pathway activation and chromatin remodelingBenigno C Valdez, Yang Li, David Murray, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|December 1, 2004
Re: Imatinib mesylate administration in the first 100 days after stem cell transplantationPaolo Anderlini, Sheetal Sheth, Krystal Hicks, et al.
British Journal of Haematology|October 29, 2000
Allogeneic haematopoietic transplantation for Richter's syndromeJ Rodriguez, M J Keating, S O'Brien, et al.
Pageof 77

Showing results (101-110 of 766) with videos related to

Sort By:
Pageof 77
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 18, 2004
Graft--versus--breast cancer effect by allogeneic hematopoietic stem-cell transplantation: a possible new frontierNaoto T Ueno, Elizabeth J Shpall, Richard E Champlin, et al.
Bone Marrow Transplantation|November 7, 2002
Long-term follow-up of normal peripheral blood progenitor cell donors treated with filgrastim: no evidence of increased risk of leukemia developmentP Anderlini, F A Chan, R E Champlin, et al.
Cancer|November 25, 2003
Sequential interleukin 3 and granulocyte-macrophage-colony stimulating factor therapy in patients with bone marrow failure with long-term follow-up of responsesHillary H Wu, Moshe Talpaz, Richard E Champlin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 10, 2010
Primary systemic amyloid light chain amyloidosis decompensating after filgrastim-induced mobilization and stem-cell collectionQaiser Bashir, Lauren A Langford, Simrit Parmar, et al.
Nature Clinical Practice. Oncology|February 1, 2008
Gonadal failure after treatment of hematologic malignancies: from recognition to management for health-care providersKazutaka Nakayama, Andrea Milbourne, Leslie R Schover, et al.
Gynecologic Oncology|January 31, 2004
Matched unrelated donor bone marrow transplantation for the treatment of platinum refractory ovarian carcinoma: a case reportMichele L Donato, Charles Levenback, David M Gershenson, et al.
The Oncologist|January 28, 2012
Phase II study of gonadotropin-releasing hormone analog for ovarian function preservation in hematopoietic stem cell transplantation patientsYee Chung Cheng, Mariko Takagi, Andrea Milbourne, et al.
Biochemical Pharmacology|October 12, 2010
The synergistic cytotoxicity of clofarabine, fludarabine and busulfan in AML cells involves ATM pathway activation and chromatin remodelingBenigno C Valdez, Yang Li, David Murray, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|December 1, 2004
Re: Imatinib mesylate administration in the first 100 days after stem cell transplantationPaolo Anderlini, Sheetal Sheth, Krystal Hicks, et al.
British Journal of Haematology|October 29, 2000
Allogeneic haematopoietic transplantation for Richter's syndromeJ Rodriguez, M J Keating, S O'Brien, et al.
Pageof 77